ecrin-mdr-crcClinical2010IPD Sharing (as of October 2019): NoColorectal cancer metastaticColorectal CancerColorectal NeoplasmsK-Ras wild type metastatic colorectal cancerK-ras Wild Type Metastatic Colorectal CancerColorectal CancerColorectal NeoplasmsColorectal Cancer MetastaticInterventionalhttps://newmdr.ecrin.org/Study/2098880AustriaBelgiumHungaryFranceSpain12Standard cetuximab + FOLFIRIFirst line metastaticK-Ras wildtypeErbitux 5 mg/ml solution for infusionCetuximabDose escalation cetuximabECRIN MDRCompletedfalseCetuximab Standard or Dose Escalation in First Line Colorectal CancerThe purposes of this study are to determine whether administering escalating doses of cetuximab in patients with no early skin toxicity could delay the progression of disease in a significant proportion of patients and to study the molecular signatures of response.2010-12-152098880NCT012515362009-009992-36